In vivo administration of escalation doses of recombinant α-Interferon (IFN-α) during a phase I trial in malignant melanoma patients caused dose-dependent increases in the mRNA accumulation, synthesis, steady state cellular content, and plasma membrane expression of class I major histocompatibility complex molecules in peripheral blood mononuclear cells. In addition, circulating levels of class I molecules were also enhanced. These findings show that (a) antigenic enhancement by biomodifiers may occur in vivo, in humans and (b) the mechanism of class I major histocompatibility complex enhancement by IFN-α is similar in vitro and in vivo. Furthermore, because peripheral blood mononuclear cells of different melanoma patients display different susceptibility to IFN-α, the entity of their antigenic modulation may represent a useful parameter to evaluate the efficacy of different therapeutic regimens and/ or assess the individual susceptibility to the molecular changes induced by IFN-α.
|Number of pages||5|
|Publication status||Published - Jan 15 1991|
ASJC Scopus subject areas
- Cancer Research